OBJECTIVES: To identify multi-attribute utility (MAU) values associated with venous thromboembolism (VTE) events and to select values for use in economic models. METHODS: A systematic review of the literature was conducted including database searches and hand-searching of relevant studies. The database search included utility studies or RCTs reporting utility scores. The disease area and population were restricted to VTE and adults, respectively. All identified economic evaluations were hand-searched in order to explore utilities from different economic evaluations. Utility sources from three previously developed economic models for rivaroxaban were also explored. Studies reporting the 8 SF-36 components were transformed to EQ-5D using a mapping model outlined by Ara and Brazier (2008). RESULTS: The database search identified 576 citations, of which 20 studies were included in the review. The hand-search identified 1 study. Two additional studies were identified from the economic models, giving a total of 23 studies. Of the 23 studies, 2 studies reported MAUs; 7 studies used direct preference based measures such as the time trade off technique and the remaining 14 studies used non-preference based measures such as SF-36. Of the 14 non-preference based measures, 5 reported mean SF-36 scores for all components and were transformed to EQ-5D. A total of 50 utility values were extracted from the studies. The selection process identified the following utility scores: 0.62 for DVT, 0.63 for PE and 0.7855 for VTE long-term complications. CONCLUSIONS: There was a large variation in the extracted utilities (0.04-0.992). Long-term disutility has greater influence than acute. Cost-utility analyses should model the relationship between acute VTE events and long-term disutility to capture all health related quality of life impairment.